Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

Article

Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Deborah Watkins Bruner, PhD, RN, FAAN, professor, Nell Hodgson Woodruff School of Nursing, Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Related Content
Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Graphic of an ovary

WRN Inhibitors May Address Immunotherapy Resistance in MSI+ Tumors

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
June 24th 2025
Article

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Image of a person holding a model of the female reproductive system

Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

Gina Mauro
June 13th 2025
Article

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

AI-generated graphic of cancer cells

T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

Chris Ryan
June 2nd 2025
Article

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.